trending Market Intelligence /marketintelligence/en/news-insights/trending/k6CgP1UegZAIPNTRlDuUHA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Illumina, Roche enter 15-year collaboration to expand gene-based cancer testing

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Illumina, Roche enter 15-year collaboration to expand gene-based cancer testing

Illumina Inc. and Roche Holding AG entered into a 15-year collaboration agreement to develop cancer testing technology that uses gene sequencing.

Under the agreement, Illumina will grant Roche rights to develop and distribute diagnostic tests that use Illumina's NextSeq 550Dx system as well as any future gene sequencing systems.

Roche will assist with new companion diagnostic claims to complement Illumina's TruSight Oncology 500 assay that is used for profiling tumor samples. Companion diagnostics are medical devices that help physicians determine whether the benefits of a particular therapy outweigh its risks.

As part of the agreement, Roche will develop Avenio in-vitro diagnostic tests, and Illumina will continue to market the sequencing system along with consumables.

In addition, both companies will collaborate to develop tests and diagnostic claims on Trusight Oncology 500 for their cancer pipelines. San Diego-based Illumina will be in charge of the development and regulatory approval process, while Roche will support the development of claims and regulatory filings.

The companies did not disclose the financial terms of the deal.